Scott Bryson

Scott Bryson is a Visiting Professor at the Strathclyde Institute of Pharmacy and Biomedical Sciences, part of the Faculty of Science at the University of Strathclyde, United Kingdom. His work spans clinical pharmacology, drug safety, and antimicrobial stewardship, with a focus on pharmacogenomics and medication-related adverse effects.

His research interests include:

• Clinical pharmacology and toxicology
• Pharmacogenomic testing in oncology (e.g., DPD deficiency)
• Iatrogenic nutrient deficiencies (e.g., copper deficiency from zinc use)
• Epidemiology of antibiotic-associated infections, particularly Clostridioides difficile
• Public health implications of antimicrobial prescribing

The recent publications highlight his contributions to understanding drug safety and personalized medicine. His work often involves large-scale data analysis and international collaboration, particularly in evaluating diagnosis, risk factors, and prescribing behaviors across healthcare systems.

His scientific contributions align with UN Sustainable Development Goals related to good health and well-being, particularly through improving medication safety and reducing preventable harm from drugs.

While no formal awards or student supervision details are listed, his peer-reviewed publications in high-impact journals reflect active engagement in translational and clinical research. He collaborates with multidisciplinary teams across the UK and internationally, including recent work involving Saudi Arabia.

He is connected through national and international research networks, contributing to policy-relevant studies using administrative and population-level health data.